Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of gu...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Res
Main Authors: Oddo, Daniele, Sennott, Erin M., Barault, Ludovic, Valtorta, Emanuele, Arena, Sabrina, Cassingena, Andrea, Filiciotto, Genny, Marzolla, Giulia, Elez, Elena, van Geel, Robin M.J.M., Bartolini, Alice, Crisafulli, Giovanni, Boscaro, Valentina, Godfrey, Jason T., Buscarino, Michela, Cancelliere, Carlotta, Linnebacher, Michael, Corti, Giorgio, Truini, Mauro, Siravegna, Giulia, Grasselli, Julieta, Gallicchio, Margherita, Bernards, René, Schellens, Jan H.M., Tabernero, Josep, Engelman, Jeffrey A., Sartore-Bianchi, Andrea, Bardelli, Alberto, Siena, Salvatore, Corcoran, Ryan B., Di Nicolantonio, Federica
פורמט: Artigo
שפה:Inglês
יצא לאור: 2016
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4970882/
https://ncbi.nlm.nih.gov/pubmed/27312529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0396
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים